Diligence memo · auto-generated · as of July 2, 2026
Cornovus Pharmaceuticals Inc.
Cornovus Pharmaceuticals Inc. looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
Cornovus Pharmaceuticals Inc. operates in Biotech / Pharma, based in FARMINGTON.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Cornovus Pharmaceuticals Inc. has raised $3.1M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $1.6M on 2014-02-28.
Most recent recorded round closed around 2024-01-22.
Valuation (modeled)modeled
Provath models Cornovus Pharmaceuticals Inc. at approximately $3.0M (range $369K–$9.1M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.18× the median modeled value of Seed Biotech / Pharma companies in 2022–2024 (14 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 59 months.
Last raise 2.4 yr ago; this sector typically re-raises about every 15 months.
Slightly overdue versus sector cadence.
The last round was 2.0× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 42% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 20% of those peers.
Closest niche peers: Outer Biosciences, LLC, Slate Bio, Inc., CASS Pharmaceuticals, Inc., FOOP Organic Biosciences, Inc., Trio Pharmaceuticals, Inc..
Peoplefiled
7 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.